Anti-TNF treatment in Crohn's disease: toward tailored therapy?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20445512.
- Also identified by DOI 10.1038/ajg.2010.15.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Infliximab is a potent therapy for induction and maintenance of remission in Crohn's disease. Unfortunately, many patients lose response and/or develop allergic reactions caused by the chimeric antibody. By means of measuring the presence of antibodies against infliximab and the trough levels of the drug, it seems easier to predict whether patients will respond to intensified dose regimens or will rather benefit from a switch to alternative agents.
Medical subject headings
- Antibodies, Monoclonal
- Crohn Disease
- Tumor Necrosis Factor-alpha